10-K: Travere Therapeutics Reports Strong FILSPARI Sales, Advances Pipeline

Travere Therapeutics' 2025 annual report highlights significant revenue growth from FILSPARI, progress in its FSGS and HCU programs, and strategic partnerships, despite ongoing clinical and market challenges.

Summary

• Full FDA approval for FILSPARI (sparsentan) in Immunoglobulin A nephropathy (IgAN) was granted on September 5, 2024, based on positive long-term confirmatory results from the PROTECT Study, demonstrating a statistically significant slowing of kidney function decline over two years compared to irbesartan (1.2 mL/min/1.73 m²/year treatment effect, p=0.0168).
• FILSPARI is the first non-immunosuppressive, oral, once-daily therapy approved for IgAN, directly targeting glomerular injury by blocking endothelin-1 and angiotensin II pathways.
• The company estimates over 70,000 addressable IgAN patients in the United States under FILSPARI's full approval indication.
• The FDA extended the review timeline for the supplemental new drug application (sNDA) for FILSPARI in focal segmental glomerulosclerosis (FSGS) to April 13, 2026, following the submission of additional responses that constituted a Major Amendment.
• Enrollment in the pivotal Phase 3 HARMONY Study for pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU), was voluntarily paused in September 2024 due to manufacturing scale-up issues but restarted in the first quarter of 2026 after process optimization.
• Total revenue increased by $257.5 million to $490.7 million in 2025, up from $233.2 million in 2024.
• FILSPARI net product sales grew by $189.8 million to $322.0 million in 2025 from $132.2 million in 2024.
• Tiopronin product sales decreased by $6.0 million to $88.5 million in 2025 from $94.5 million in 2024, primarily due to increased generic competition.
• License and collaboration revenue increased by $73.8 million to $80.3 million in 2025, driven by $57.5 million in market access and regulatory milestones from CSL Vifor and $10.2 million from the sale of Renalys stock to Chugai.
• Net loss significantly decreased to $25.5 million in 2025 from $321.5 million in 2024.
• Cash and cash equivalents increased to $93.0 million as of December 31, 2025, from $58.5 million as of December 31, 2024.
• The company recognized a $25.0 million sales milestone from Mirum Pharmaceuticals in 2025, related to its divested bile acid product portfolio, with payment expected in Q2 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, driven by strong FILSPARI commercial performance and significant milestone achievements, which substantially reduced the net loss and generated positive operating cash flow. However, the FSGS regulatory delay and the manufacturing pause for pegtibatinase introduce some caution regarding pipeline timelines.

Positives

• Full FDA approval for FILSPARI (sparsentan) in IgAN on September 5, 2024, based on long-term confirmatory results from the PROTECT Study, demonstrating a statistically significant slowing of kidney function decline.
• FILSPARI is the first non-immunosuppressive, oral, once-daily therapy approved for IgAN, offering a unique treatment mechanism.
• Significant increase in FILSPARI net product sales, reaching $322.0 million in 2025 compared to $132.2 million in 2024.
• Conversion of conditional marketing authorization to standard marketing authorization for FILSPARI in Europe and the UK, expanding commercial reach.
• Received $17.5 million regulatory milestone payment and a $40.0 million market access milestone payment from CSL Vifor in 2025.
• Positive topline results from Renalys' (now Chugai) Phase 3 study of sparsentan in Japanese IgAN patients, indicating potential for future market expansion.
• Received $10.2 million from the acquisition of Renalys by Chugai Pharmaceutical Co., Ltd., as a minority shareholder.
• The FDA accepted the sNDA for FILSPARI in FSGS and subsequently informed the company that an advisory committee meeting was no longer needed, potentially streamlining the approval process.
• Restarted enrollment in the pivotal Phase 3 HARMONY Study for pegtibatinase in HCU in Q1 2026, following successful manufacturing process optimization.
• Net loss substantially decreased to $25.5 million in 2025 from $321.5 million in 2024.
• Generated positive cash flow from operating activities of $37.8 million in 2025, a significant improvement from cash used of $230.0 million in 2024.
• Management believes available cash and short-term investments are sufficient to fund anticipated operations beyond the next 12 months.

Negatives

• Tiopronin product sales decreased by $6.0 million in 2025 due to increased generic competition.
• The Phase 3 DUPLEX Study of sparsentan in FSGS did not achieve its two-year primary eGFR slope endpoint with statistical significance over the active control irbesartan.
• The FDA extended the review timeline for the sNDA for FILSPARI in FSGS to April 13, 2026, due to the submission of additional responses, which constituted a Major Amendment.
• A voluntary pause in enrollment for the Phase 3 HARMONY Study for pegtibatinase was enacted in September 2024 due to issues with achieving the desired drug substance profile in the initial manufacturing scale-up.
• The accumulated deficit increased to $1,472.7 million in 2025 from $1,447.2 million in 2024.
• Received an invoice for approximately $6.2 million from the French government for recalculated rebates on the previously marketed product Kolbam, which was paid while an appeal is being pursued.

Risks

• Future prospects are highly dependent on the ability to successfully develop and execute commercialization strategies for products, including FILSPARI, and to attain market acceptance among physicians, patients, and healthcare payers.
• The company needs to continue developing its commercial organization, including maintaining a highly experienced and skilled workforce with qualified sales representatives.
• Substantial generic and other competition could adversely affect operating results, particularly for Thiola and Thiola EC, and potentially for FILSPARI following the expiration of patent or regulatory exclusivity.
• Healthcare reform initiatives, unfavorable pricing regulations, and changes in reimbursement practices of third-party payers or patients' access to insurance coverage could affect the pricing of and demand for products.
• Dependence on third parties for manufacturing and distribution, with current sole-source suppliers for FILSPARI and Thiola, poses risks to supply, quality, and cost.
• Clinical trials are expensive, time-consuming, and may fail to demonstrate the safety and efficacy of product candidates.
• Success in nonclinical testing and early clinical trials does not ensure that later clinical trials will be successful.
• Communications and/or feedback from regulatory authorities related to current or planned future clinical trials do not guarantee any particular outcome or timeline for regulatory review, and expedited pathways may not lead to faster development or approval.
• Interim, topline, and preliminary data from clinical trials that are announced or published may change materially as more patient data become available and audit and verification procedures are complete.
• The market opportunities for products and product candidates may be smaller than believed.
• Product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or commercialization.
• The company does not currently have patent protection for certain commercial products (e.g., original Thiola formulation), and the inability to obtain and maintain intellectual property protection could adversely affect their value.
• Reliance on orphan drug status for certain products and product candidates may not confer marketing exclusivity or other expected commercial benefits.
• Inability to obtain and maintain coverage and adequate reimbursement from governments or third-party payers for any products, or acceptable prices, would harm revenue and profitability.
• International trade policies, including tariffs, sanctions, and trade barriers (e.g., BIOSECURE Act impacting Chinese suppliers), may adversely affect business, financial condition, results of operations, and prospects.
• The company will likely experience fluctuations in operating results and could incur substantial losses.
• Negative publicity regarding any products could impair the ability to market them and may require significant time and money to address.
• The company may need substantial funding and may be unable to raise capital when needed, especially given general market conditions.
• The company may not receive some or all of the potential milestone and/or royalty payments from corporate and licensing transactions.
• The company may be unable to successfully integrate new products or businesses acquired.
• Product liability lawsuits against the company could cause substantial liabilities and limit commercialization of any products.
• Involvement in litigation matters could result in substantial costs, divert management's attention, and otherwise have a material adverse effect on business, operating results, or financial condition.
• The company is subject to significant ongoing regulatory obligations and oversight, which may result in significant additional expense and may limit commercial success.
• Unstable market, economic, and geopolitical conditions may have serious adverse consequences on business, financial condition, and stock price.
• Dependence on a highly experienced and skilled workforce; inability to attract, retain, and engage employees could hinder effective growth.
• Health epidemics or pandemics could materially adversely affect business, results of operations, and financial condition.
• Material weaknesses in internal control over financial reporting, if discovered or occurring in the future, could lead to material misstatements and restatements, adversely affecting stock price and compliance.
• Adverse developments affecting the financial services industry could adversely affect current and projected business operations and financial condition.
• Indebtedness, specifically the $316 million in 2.25% Convertible Senior Notes due 2029, could adversely affect financial condition by requiring a portion of cash flow for interest and principal payments.
• The company may be unable to raise the funds necessary to repurchase the 2029 Notes for cash following a fundamental change, or to pay any cash amounts due upon conversion.
• Provisions of the 2029 Notes could discourage an acquisition of the company by a third party.
• Conversion of the 2029 Notes may dilute the ownership interest of existing stockholders.
• Business could be negatively impacted by environmental, social, and corporate governance (ESG) matters or reporting of such matters.
• The withdrawal of the United Kingdom from the European Union (Brexit) may adversely impact the ability to obtain regulatory approvals and increase expenses in the United Kingdom.
• Risks related to the use of artificial intelligence technologies could adversely affect business, financial condition, and/or operating results.
• Uncertainties in the interpretation and application of existing, new, and proposed tax laws and regulations could materially affect tax obligations and effective tax rate.
• The ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income and taxes may be subject to limitations.
• Changes in funding for the FDA, the SEC, and other government agencies or regulatory authorities could hinder their ability to perform normal functions, negatively impacting the business.

Future Outlook

Management believes that available cash and short-term investments are sufficient to fund anticipated operations beyond the next 12 months. The company expects operating results to vary significantly due to ongoing R&D investments and clinical development activities, and anticipates continued significant commercialization expenses for FILSPARI and any other future approved products. Chugai plans to file for regulatory approval for sparsentan in Japan in 2026. The company will continue to evaluate potential opportunities to expand its pipeline and approved products through licenses and acquisitions and intends to use continued clinical trial experience with FILSPARI and post-marketing data to potentially support lifting of the liver monitoring REMS in the future.

Management Comments

• Management believes our ability to continue our operations depends on our ability to sustain and grow revenue, results of operations and our ability to access capital markets when necessary to accomplish our strategic objectives.
• Management believes that we may incur losses in the immediate future.
• Management believes our current facilities are adequate to conduct our business, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms.

Industry Context

StockSavvy.ai notes that Travere Therapeutics operates in the highly competitive and rapidly evolving rare kidney and metabolic disease space. The full FDA approval of FILSPARI for IgAN positions it as a foundational kidney-targeted therapy, aligning with updated Kidney Disease Improving Global Outcomes (KDIGO) guidelines that advocate for early, risk-appropriate treatment. The market is seeing increasing competition from other kidney-targeted agents like Novartis' atrasentan and SGLT2 inhibitors (e.g., AstraZeneca's Farxiga/Forxiga, Boehringer Ingelheim and Eli Lilly's Jardiance), as well as a growing group of novel immune-targeted therapies (e.g., APRILand BAFF-pathway inhibitors like Otsuka's sibeprenlimab, complement pathway inhibitors like Novartis' iptacopan). The challenges in FSGS development, as seen with the DUPLEX study's primary endpoint, reflect the broader difficulties in establishing clear clinical endpoints for rare kidney diseases, though the PARASOL project's alignment on proteinuria-based endpoints offers a potential path forward. The generic competition for Thiola highlights the constant pressure on older, established rare disease therapies.

Comparison to Industry Standards

• FILSPARI is the only therapy to date to demonstrate a statistically significant slowing of kidney function decline in a Phase 3 study compared to an active, maximally titrated RAS inhibitor (irbesartan) in IgAN.
• FILSPARI is the first non-immunosuppressive therapy approved for IgAN and the only oral, once-daily, non-immunosuppressive therapy approved for this condition that directly targets glomerular injury.
• If approved, FILSPARI could become the first and only FDA-approved medicine indicated for FSGS, addressing a high unmet need with no currently approved pharmacologic treatments.
• Pegtibatinase is being developed as the first disease-modifying therapy for classical HCU, where current treatment options are limited to protein-restricted diet and supplemental use of vitamin B6 and betaine.
• The DUPLEX study for FSGS, while not meeting its primary eGFR endpoint with statistical significance, showed statistically significant and clinically meaningful proteinuria remission at 36 weeks that was durable through 2 years, and patients achieving remission had a 67% to 77% lower risk of kidney failure, aligning with independent PARASOL workgroup findings on the importance of proteinuria in FSGS.

Corporate Governance

Legal Proceedings

• In October 2021, the company's distributor in France for the previously marketed product Kolbam received a notice of recalculated price from the pharmaceutical pricing agency. An invoice for approximately $6.2 million was received in October 2024 and paid in November 2024. The company has filed an appeal with the Competent Administrative Court regarding this matter.
• In 2020, the company completed its response to a civil investigative demand from the U.S. Federal Trade Commission (FTC) related to the marketing, sale, distribution, and pricing of its products, including Thiola. The investigation remains open, but the FTC has not indicated additional questions or initiated any claim or proceeding against the company relating to these matters.

Stakeholder Impact

• Shareholders: Potential for dilution from convertible notes and future equity raises; positive impact from increased revenue and reduced net loss; risk from stock price volatility and unstable market conditions.
• Patients: Continued access to FILSPARI for IgAN; potential new treatment options for FSGS (FILSPARI) and HCU (pegtibatinase); improved liver monitoring for FILSPARI.
• Employees: Workforce reduction of approximately 20% in December 2023 (non-field-based); ongoing focus on attracting, retaining, and developing a highly skilled workforce; competitive compensation and benefits.
• Healthcare Providers: Continued education and training on the company's products; evolving treatment guidelines for IgAN.
• Payers: Impact of healthcare reform initiatives, unfavorable pricing regulations, and changes in reimbursement practices.
• Suppliers/Manufacturers: Continued dependence on third-party manufacturers, including sole-source suppliers; risks from supply chain disruptions, geopolitical factors, and regulatory compliance.
• Creditors: The company's indebtedness (Convertible Senior Notes Due 2029) requires a portion of cash flow for interest and principal payments, and the company's ability to meet these obligations depends on future performance and access to capital.

Next Steps

• FDA review of the sNDA for FILSPARI in FSGS, with a new PDUFA target action date of April 13, 2026.
• Chugai Pharmaceutical Co., Ltd. plans to file for regulatory approval for sparsentan in Japan in 2026.
• Continue to evaluate potential opportunities to expand the pipeline and approved products through licenses and acquisitions.
• Continue efforts to support lifting of the liver monitoring Risk Evaluation and Mitigation Strategy (REMS) for FILSPARI in the future, following sufficient experience and supporting data.
• Pursue an appeal of the $6.2 million French rebate invoice with the Competent Administrative Court.
• Monitor potential historical ownership changes that could limit the use of net operating loss carryforwards.
• Engage in trilogue negotiations between the Council, Parliament, and European Commission regarding the new Directive and Regulation to revise pharmaceutical legislation.
• The MHRA in the UK is working with UK HTA bodies to introduce new pathways supporting innovative approaches to medicinal products.

Key Dates

Recommendation

The company demonstrated strong commercial execution with FILSPARI, leading to substantial revenue growth and a significant reduction in net loss. The progress in the FSGS sNDA and the restart of the HARMONY study are positive, but the FSGS primary endpoint miss and the HCU manufacturing delay introduce uncertainty. While the financial trajectory is improving, the company still faces substantial R&D costs, generic competition for Thiola, and the need for future capital, warranting a cautious 'Hold' as the pipeline matures and market acceptance solidifies.

Keywords

Biopharmaceutical, Rare Kidney Disease, Metabolic Disease, FILSPARI, sparsentan, IgAN, FSGS, pegtibatinase, HCU, Thiola, Thiola EC, Cystinuria, FDA Approval, Clinical Trials, Orphan Drug, Commercialization, SEC Filing, 10-K, Travere Therapeutics, Drug Development, Biotechnology